140 related articles for article (PubMed ID: 31310811)
1. Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock.
Hongisto M; Kataja A; Tarvasmäki T; Holopainen A; Javanainen T; Jurkko R; Jäntti T; Kimmoun A; Levy B; Mebazaa A; Pulkki K; Sionis A; Tolppanen H; Wollert KC; Harjola VP; Lassus J;
J Card Fail; 2019 Nov; 25(11):894-901. PubMed ID: 31310811
[TBL] [Abstract][Full Text] [Related]
2. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial.
Fuernau G; Poenisch C; Eitel I; de Waha S; Desch S; Schuler G; Adams V; Werdan K; Zeymer U; Thiele H
Eur J Heart Fail; 2014 Aug; 16(8):880-7. PubMed ID: 24903195
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock - Insights from the CardShock study.
Kataja A; Tarvasmäki T; Lassus J; Sionis A; Mebazaa A; Pulkki K; Banaszewski M; Carubelli V; Hongisto M; Jankowska E; Jurkko R; Jäntti T; Kasztura M; Parissis J; Sabell T; Silva-Cardoso J; Spinar J; Tolppanen H; Harjola VP;
Int J Cardiol; 2021 Jan; 322():191-196. PubMed ID: 32841617
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients.
Heringlake M; Charitos EI; Gatz N; Käbler JH; Beilharz A; Holz D; Schön J; Paarmann H; Petersen M; Hanke T
J Am Coll Cardiol; 2013 Feb; 61(6):672-81. PubMed ID: 23391200
[TBL] [Abstract][Full Text] [Related]
5. Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome.
Tolppanen H; Rivas-Lasarte M; Lassus J; Sadoune M; Gayat E; Pulkki K; Arrigo M; Krastinova E; Sionis A; Parissis J; Spinar J; Januzzi J; Harjola VP; Mebazaa A;
Crit Care Med; 2017 Jul; 45(7):e666-e673. PubMed ID: 28403119
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.
Fuernau G; Pöss J; Denks D; Desch S; Heine GH; Eitel I; Seiler S; de Waha S; Ewen S; Link A; Schuler G; Adams V; Böhm M; Thiele H
Crit Care; 2014 Dec; 18(6):713. PubMed ID: 25528363
[TBL] [Abstract][Full Text] [Related]
7. The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock - Results from the CardShock Study.
Kataja A; Tarvasmäki T; Lassus J; Cardoso J; Mebazaa A; Køber L; Sionis A; Spinar J; Carubelli V; Banaszewski M; Marino R; Parissis J; Nieminen MS; Harjola VP
Int J Cardiol; 2017 Jan; 226():48-52. PubMed ID: 27788389
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock.
Hongisto M; Lassus J; Tarvasmäki T; Sans-Roselló J; Tolppanen H; Kataja A; Jäntti T; Sabell T; Banaszewski M; Silva-Cardoso J; Parissis J; Jurkko R; Spinar J; Castrén M; Mebazaa A; Masip J; Harjola VP;
Eur Heart J Acute Cardiovasc Care; 2022 Aug; 11(10):731-8. PubMed ID: 35949144
[TBL] [Abstract][Full Text] [Related]
9. Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock.
Hänninen M; Jäntti T; Tolppanen H; Segersvärd H; Tarvasmäki T; Lassus J; Vausort M; Devaux Y; Sionis A; Tikkanen I; Harjola VP; Lakkisto P; For The CardShock Study Group
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114482
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor-15 in Takotsubo cardiomyopathy: diagnostic and prognostic value.
Stiermaier T; Adams V; Just M; Blazek S; Desch S; Schuler G; Thiele H; Eitel I
Int J Cardiol; 2014 May; 173(3):424-9. PubMed ID: 24681016
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease.
Li M; Duan L; Cai YL; Li HY; Hao BC; Chen JQ; Liu HB
Cardiovasc Diabetol; 2020 Aug; 19(1):120. PubMed ID: 32746821
[TBL] [Abstract][Full Text] [Related]
12. Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock.
Jäntti T; Tarvasmäki T; Harjola VP; Parissis J; Pulkki K; Javanainen T; Tolppanen H; Jurkko R; Hongisto M; Kataja A; Sionis A; Silva-Cardoso J; Banaszewski M; Spinar J; Mebazaa A; Lassus J;
PLoS One; 2019; 14(5):e0217006. PubMed ID: 31095609
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock.
Jäntti T; Segersvärd H; Tolppanen H; Tarvasmäki T; Lassus J; Devaux Y; Vausort M; Pulkki K; Sionis A; Bayes-Genis A; Tikkanen I; Lakkisto P; Harjola VP
ESC Heart Fail; 2019 Feb; 6(1):98-102. PubMed ID: 30472788
[TBL] [Abstract][Full Text] [Related]
14. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.
Hao J; Cheang I; Zhang L; Wang K; Wang HM; Wu QY; Zhou YL; Zhou F; Xu DJ; Zhang HF; Yao WM; Li XL
Chin Med J (Engl); 2019 Oct; 132(19):2278-2285. PubMed ID: 31567379
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor-15 predicts poor survival after cardiac arrest.
Richter B; Uray T; Krychtiuk KA; Schriefl C; Lenz M; Nürnberger A; Kastl SP; Wojta J; Heinz G; Schwameis M; Speidl WS
Resuscitation; 2019 Oct; 143():22-28. PubMed ID: 31394153
[TBL] [Abstract][Full Text] [Related]
16. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
17. Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study.
Hongisto M; Lassus J; Tarvasmäki T; Sionis A; Sans-Rosello J; Tolppanen H; Kataja A; Jäntti T; Sabell T; Lindholm MG; Banaszewski M; Silva Cardoso J; Parissis J; Di Somma S; Carubelli V; Jurkko R; Masip J; Harjola VP;
ESC Heart Fail; 2021 Apr; 8(2):1398-1407. PubMed ID: 33522124
[TBL] [Abstract][Full Text] [Related]
18. Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock.
Tolppanen H; Rivas-Lasarte M; Lassus J; Sans-Roselló J; Hartmann O; Lindholm M; Arrigo M; Tarvasmäki T; Köber L; Thiele H; Pulkki K; Spinar J; Parissis J; Banaszewski M; Silva-Cardoso J; Carubelli V; Sionis A; Harjola VP; Mebazaa A
Ann Intensive Care; 2017 Dec; 7(1):6. PubMed ID: 28050899
[TBL] [Abstract][Full Text] [Related]
19. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study.
Kempf T; Sinning JM; Quint A; Bickel C; Sinning C; Wild PS; Schnabel R; Lubos E; Rupprecht HJ; Münzel T; Drexler H; Blankenberg S; Wollert KC
Circ Cardiovasc Genet; 2009 Jun; 2(3):286-92. PubMed ID: 20031597
[TBL] [Abstract][Full Text] [Related]
20. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy.
Damman P; Kempf T; Windhausen F; van Straalen JP; Guba-Quint A; Fischer J; Tijssen JG; Wollert KC; de Winter RJ; Hirsch A;
Int J Cardiol; 2014 Mar; 172(2):356-63. PubMed ID: 24502880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
